Types of lupus nephritis exacerbations: prognostic significance


Cite item

Full Text

Abstract

Aim. To characterize the course of lupus nephritis (LN) in terms of demographic indices (sex, age of renal disease onset), the presence of antiphospholipid syndrome (APS) and to ascertain a prognostic role of the disease exacerbations. Material and methods. A total of 121 LN patients were followed up from 1997 to 2004 (mean duration of the follow-up 5.6 ± 6.4 years). A LN course was characterized by the presence of a complete or partial remission, exacerbation of the disease, repeated hospitalisations. Two types of exacerbations were considered: proteinuric, running with progressive proteinuria and normal renal function (type 1); functional, running with elevation of blood creatinine (type 2). Results. Exacerbations were observed in one third of the examinees, 70% of them ran with renal dysfunction. Exacerbations occurred more frequently in males than in females (50 vs 27%, respectively; p=0.08) and in patients with early onset of LN (at the age of 40 years and younger, 80 vs 60%, respectively; p<0.05). Exacerbations of type 2 occurred in males, in patients with early onset of renal damage and in APS association. It is shown that LN exacerbations, their incidence and type (a functional type) have a negative influence on renal survival of the patients. Conclusion. Identification of groups of LN patients at high risk of exacerbations and unfavourable prognostic role of exacerbations dictates the necessity of due immunosuppressive therapy for maintenance of remission.

About the authors

N A Samokishina

ММА им. И. М. Сеченова

N L Kozlovskaia

ММА им. И. М. Сеченова

E M Shilov

ММА им. И. М. Сеченова

V A Varshavskiĭ

ММА им. И. М. Сеченова

N G Miroshnichenko

ММА им. И. М. Сеченова

References

  1. Korbet S. М. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am. J. Kidney Dis. 2000; 35: 904-914.
  2. Шилов E. M. Иммуносупрессивная терапия активных форм нефритов (клинико-экспериментальное исследование): Автореф. дис. ... д-ра мед. наук. М.; 1994.
  3. Cameron J. S. Lupus nephritis. J. Am. Soc. Nephrol. 1999; 10: 413-424.
  4. Moroni G., Quaglini S., Maccario M. et al. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996; 50 (6): 2047-2053.
  5. Козловская H. Л. Нефропатия, ассоциированная с антифосфолипидным синдромом: клинико-морфологическая характеристика, диагностика, лечение: Автореф. дис. ... д-ра мед. наук. М.; 2006.
  6. Wang С., Liu Y., Wang Н. Lupus nephritis in male adults, an analysis of the clinical and pathological features. Zhonghua Nei Ke Za Zhi 1995; 34: 827-830.
  7. Li H., Li X., Chu G. et al. A clinical analysis of 62 male patients with lupus nephritis. Zhongguo Yi Xue Yuan Xue Bao 2000; 22 (4): 395-397.
  8. Мок С. C., Wong R. W., Lau C. S. Lupus nephritis in southern Chinese patients: clinicopathologic findings and long-term outcome. Am. J. Kidney Dis. 1999; 34: 315-323.
  9. Ciruelo E., de la Crus J., Lopez I., Gomez-Reino J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthr. and Rheum. 1996; 12: 2028-2034.
  10. Petri M. Systemic lupus erythematosus. Hopkins lupus cohort. Rheum. Dis. Clin. N. Am. 2000; 26 (2): 199-213.
  11. Jonson H, Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-150.
  12. Mirzayan M. J., Schmidt A., Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology 2000; 39: 1316-1319.
  13. Ioannidis J. P., Boki K. A., Katsorida M. E. et al. Remission, relapse and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000; 57: 258-264.
  14. Contreras G., Pardo V., Leclercq B. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 2004; 350: 971-980.
  15. Sidiropoulos P. I., Kritikos H. D., Boumpas D. T. Lupus nephritis flares. Lupus 2005; 14: 49-52.
  16. Моc С. С. Prognostic factors in lupus nephritis. Lupus 2005; 14: 39-44.
  17. Янушкевич Т. H. Оценка факторов, влияющих на течение и прогноз волчаночного нефрита: Дис. ... канд. мед. наук. М.; 1981.
  18. Cabral A. R. Autoantibodies in systemic lupus erythematosus. Curr. Opin. Rheumatol. 1998; 10: 409-416.
  19. Winfield J. В., Fuferman I., Kaffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. J. Clin. Invest. 1977; 59: 90-96.
  20. Bootsma H., Spronk P., Derksen R. et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
  21. Cortes-Hernandez J., Ordi-Ros J., Labrador M. et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am. J. Med. 2004; 116: 165-173.
  22. Swaak A. J. G., Nossent J. S., Bronsveld W. et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann. Rheum. Dis. 1989; 48: 447-460.
  23. Но С. Т. К., Мок С. C., Lau C. S., Wong R. W. S. Late onset systemic lupus erythematosus in southern Chinese. Ann. Rheum. Dis. 1998; 57: 437-440.
  24. Donadio J. V., Hart G. M., Bergstralh E. J., Holley К. E. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-115.
  25. Мок С. С., Но C. N., Chan K. W. et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthr. and Rheum. 2002; 46: 1003-1013.
  26. Mosca M., Neri R., Giannessi S. et al. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10: 253-257.
  27. Козловская H. Л., Шилов E. M., Метелева H. А. и др. Клинические и морфологические особенности волчаночного нефрита при системной красной волчанке с антифосфолипидным синдромом. Тер. арх. 2006; 5: 21-31.
  28. Daugas Е., Nochy D., Тhi Huong D. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 2002; 13: 42-52.
  29. Farrugia E., Torres V. E., Gastineau D. et al. Lupus anticoagulant in systemic lupus erythematosus: a clinical and pathological study. Am. J. Kidney Dis. 1992; 5: 463-471.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies